Myeloperoxidase, modified lipoproteins, and atherogenesis

Stephen J. Nicholls, Stanley L. Hazen

Research output: Contribution to journalReview ArticleOtherpeer-review

172 Citations (Scopus)


Numerous lines of evidence implicate a role for myeloperoxidase (MPO) in the pathogenesis of atherosclerosis. Enriched within vulnerable plaque, MPO serves as an enzymatic source of eicosanoids and bioactive lipids and generates atherogenic forms of both low- and high-density lipoproteins. These factors likely contribute to clinical studies demonstrating that increased systemic levels of MPO and its oxidation products predict increased cardiovascular risk. As a result, interest has focused on the potential to target MPO for the development of new risk markers, imaging, and therapies to prevent cardiovascular events.

Original languageEnglish
Pages (from-to)S346-351
Number of pages6
JournalJournal of Lipid Research
Issue numberSUPPL.
Publication statusPublished - 1 Apr 2009
Externally publishedYes


  • Free radicals
  • High density lipoprotein
  • Oxidant stress
  • Scavenger receptor

Cite this